An 8 Week Phase Ib, Monocentric, Randomized, Double-masked, Vehicle Controlled, Parallel Groups, Study With a 24 Week Follow-up Period to Evaluate the Safety and Potential Efficacy of a 180 μg/ml Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Glaucoma
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Cenegermin (Primary)
- Indications Glaucoma
- Focus Therapeutic Use
- Acronyms NGF-Glaucoma
- Sponsors Dompe Farmaceutici
- 23 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.
- 23 Jan 2017 Status changed from not yet recruiting to recruiting.
- 12 Jan 2017 Planned End Date changed from 1 Sep 2017 to 1 Feb 2018.